Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1130.3000 10.40 (0.93%)
NSE Oct 10, 2025 15:31 PM
Volume: 1.5M
 

1130.30
0.93%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Aurobindo Pharma has acquired the Generis group in Portugal (subject to the fulfilment of certain anti-trust approvals), through its step down subsidiary Agile Pharma (Netherlands) for a consideration of ~135 million (~| 985 crore). The consideration is proposed to be financed via European debt. Generis' CY16 revenues were 64.8 million and EBITDA was 12.7 million. In CY17, the management expects revenues to increase to ~73 million and EBITDA to ~16 million mainly from new launches and...
Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.
More from Aurobindo Pharma Ltd.
Recommended